Sugi Predict

Sugi Predict / Compounds / Trifluoroacetic Acid

Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL1787547

NC(=O)c1ccccn1.O=C(O)C(F)(F)F

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 3/20 0.55
▸ LMNA P02545 2/20 0.55
▸ NAPRT Q6XQN6 1/20 0.55
▸ P4HTM Q9NXG6 1/20 0.55
▸ CES2 O00748 1/20 0.52
▸ CES1 P23141 1/20 0.52
▸ KMT2A Q03164 4/20 0.50
▸ ALDH1A1 P00352 4/20 0.48
▸ MAPK1 P28482 1/20 0.47
▸ NPC1 O15118 3/20 0.46
▸ RAB9A P51151 3/20 0.46
▸ PKM P14618 2/20 0.46
▸ MITF O75030 1/20 0.46
▸ CDK5 Q00535 1/20 0.46
▸ CDK5R1 Q15078 1/20 0.46
▸ TLR7 Q9NYK1 1/20 0.45
▸ GSK3B P49841 1/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ CTNNB1 P35222 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL28314966 1.00 L3MBTL1 (0.55) L3MBTL1LMNANAPRTP4HTMCES2
Trifluoroacetic Acid SCHEMBL30261497 1.00 L3MBTL1 (0.55) L3MBTL1LMNANAPRTP4HTMCES2
SCHEMBL1505348 0.87 — —
SCHEMBL4914089 0.87 CES2 (0.67) L3MBTL1LMNANAPRTP4HTMCES2
SCHEMBL61183 0.87 — —
Trifluoroacetic Acid SCHEMBL31078804 0.86 LMNA (0.52) L3MBTL1LMNANAPRTP4HTMCES2
2-Picolinic Acid SCHEMBL7652543 0.85 LMNA (0.77) L3MBTL1LMNANAPRTP4HTMCES2
Fluoromethane SCHEMBL27831743 0.85 ALDH1A1 (0.61) L3MBTL1LMNANAPRTP4HTMCES2
SCHEMBL9094627 0.85 CES2 (0.64) L3MBTL1LMNANAPRTP4HTMCES2
Hydrochloric Acid SCHEMBL1704886 0.85 CES2 (0.64) L3MBTL1LMNANAPRTP4HTMCES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110234637-A Pyrazole amide compounds useful as IRAK inhibitors 里格尔药品股份有限公司 2019-09-13 — — CN claimed
CN-105283443-B Hete rocyclic derivatives and application thereof 株式会社C&C新药研究所 2018-08-17 — — CN claimed
CN-106458982-A Indazole compounds as irak4 inhibitors 奥列基因发现技术有限公司 2017-02-22 — — CN claimed
CN-105431430-A Bace1 inhibitors HOFFMANN LA ROCHE 2016-03-23 — — CN claimed
US-20250082644-A1 COMBINATION THERAPIES FOR THE TREATMENT OF CANCER CURIS, INC. 2025-03-13 — — US disclosed
US-12178821-B2 Combination therapies for the treatment of cancer CURIS, INC. (US) 2024-12-31 — — US disclosed
WO-2023003014-A1 METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE 中外製薬株式会社 2023-01-26 — — WO disclosed
US-20220370422-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS CURIS, INC. 2022-11-24 — — US disclosed
US-20220339161-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS AURIGENE ONCOLOGY LIMITED (IN) 2022-10-27 — — US disclosed
US-11419875-B2 Compounds and compositions for treating hematological disorders AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2022-08-23 — — US disclosed
CN-114245796-A Imidazo [1,2-a ] pyridinyl derivatives and their use in the treatment of disease 比奥根MA公司 2022-03-25 — — CN disclosed
WO-2022018875-A1 ARYLAMIDE DERIVATIVE-CONTAINING PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CELL PROLIFERATION DISEASES 中外製薬株式会社 2022-01-27 — — WO disclosed
CN-100348599-C Novel fused imidazole derivatives EISAI CO LTD (JP) 2007-11-14 — — CN disclosed
CN-1931859-A New fused imidazole derivative EISAI CO LTD (JP) 2007-03-21 — — CN disclosed
CN-1894238-A Diamine derivatives DAIICHI SEIYAKU CO (JP) 2007-01-10 — — CN disclosed
CN-1826333-A Diamine derivatives DAIICHI SEIYAKU CO (JP) 2006-08-30 — — CN disclosed
CN-1751025-A Diamine derivatives DAIICHI SEIYAKU CO (JP) 2006-03-22 — — CN disclosed
CN-1700911-A Combination drug EISAI CO LTD (JP) 2005-11-23 — — CN disclosed
CN-1675208-A Novel fused imidazole derivatives EISAI CO LTD (JP) 2005-09-28 — — CN disclosed
CN-1649581-A Substituted 3-amino-thieno [2, 3-b ] pyridine-2-carboxylic acid amide compounds, preparation method and uses thereof BOEHRINGER INGELHEIM PHARMA (US) 2005-08-03 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250082644-A1 COMBINATION THERAPIES FOR THE TREATMENT OF CANCER IRAK4, IRAK2, IRAK3 L3MBTL1 423/4885LMNA 1654/4885NAPRT 989/4885
US-20220370422-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS IRAK4, IRAK2, JAK2 L3MBTL1 1155/4885LMNA 1703/4885NAPRT 3749/4885
US-11419875-B2 Compounds and compositions for treating hematological disorders IRAK4, FLT3, IRAK3 L3MBTL1 1307/4885LMNA 2422/4885NAPRT 2192/4885
US-12178821-B2 Combination therapies for the treatment of cancer IRAK4, IRAK2, IRAK3 L3MBTL1 423/4885LMNA 1654/4885NAPRT 989/4885
US-20220339161-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS IRAK4, FLT3, IRAK3 L3MBTL1 1307/4885LMNA 2422/4885NAPRT 2192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.